


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method of treating a warm-blooded animal having myeloma comprising ~~an epothilone of formula IB~~



wherein ~~A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond,~~
or a pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): The method according to claim 1 wherein the warm-blooded animal is a human.

Claim 3 (previously presented): The method according to claim 1 wherein the myeloma is resistant to conventional cytotoxic chemotherapy.

Claim 4 (previously presented): The method according to claim 1 wherein overexpression of the multi-drug resistance protein p170 is observed.

Claim 5 (currently amended): The method according to claim 1 wherein the myeloma is resistant to a taxane[~~(,)]~~ ~~e.g., paclitaxel~~.

Claim 6 (previously presented): The method according to claim 1 wherein the disease is multiple myeloma.

Claim 7 (canceled)

Claim 8 (currently amended): The method according to claim ~~7~~1 comprising administering epothilone B weekly in a dose that is between about 0.1 to 6 mg/m² for three weeks after an interval of one to six weeks after the preceding treatment.

Claim 9-17 (canceled)